<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6659B26F-D155-4434-9E44-7B2281023718"><gtr:id>6659B26F-D155-4434-9E44-7B2281023718</gtr:id><gtr:name>Mission Therapeutics Limited</gtr:name><gtr:address><gtr:line1>BABRAHAM HALL , BABRAHAM</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6659B26F-D155-4434-9E44-7B2281023718" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>6659B26F-D155-4434-9E44-7B2281023718</gtr:id><gtr:name>Mission Therapeutics Limited</gtr:name><gtr:address><gtr:line1>BABRAHAM HALL , BABRAHAM</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1892918.0</gtr:offerGrant><gtr:projectCost>3154863.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C18FDFA4-F713-4B40-801B-03A4ECF056D8"><gtr:id>C18FDFA4-F713-4B40-801B-03A4ECF056D8</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102419"><gtr:id>F3C6BF45-DFEB-48C9-80C1-1AA0969B1A5E</gtr:id><gtr:title>Development of USP7 inhibitors for cancer therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102419</gtr:grantReference><gtr:abstractText>MISSION Therapeutics, a UK-based SME is a world-leading expert in deubiquitylating enzyme (DUB) drug

discovery, with a number of projects in lead optimisation. Through counter-screening our ongoing

projects, we identified a small molecule inhibtiors of a DUB drug target with potential to be developed

for treating soft tissue sarcomas and other cancers with clear unmet need and significant market

potential. In this project we aim to pursue and develop these inhibitors with the overall objective of

producing first-in-class DUB inhibitors as treatments for some of the most difficult to treat cancers.</gtr:abstractText><gtr:fund><gtr:end>2017-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1892918</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102419</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>